A Phase II Trial of iTTo in Advanced Gastric and GEJ Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and feasibility of Irinotecan, Trifluridine/Tipiracil
(TAS-102) and Oxaliplatin (iTTo) for treatment naïve advanced gastric or gastroesophageal
junction adenocarcinoma.